96% of Covid-19 patients recover in Beacon pharma’s Favipira trial
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Sunday
July 03, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SUNDAY, JULY 03, 2022
96% of Covid-19 patients recover in Beacon pharma’s Favipira trial

Covid-19 in Bangladesh

TBS Report
08 July, 2020, 08:10 pm
Last modified: 09 July, 2020, 11:20 am

Related News

  • Recover secures $100m minority equity investment from Goldman Sachs
  • Spanish recycled cotton producer opens new facility in Bangladesh
  • Beacon Pharma: Price Sensitive Information
  • Beacon Pharma’s profit up on sales growth
  • Dutch Covid-19 patients transferred to Germany as hospitals struggle

96% of Covid-19 patients recover in Beacon pharma’s Favipira trial

Forty-eight percent of Covid-19 patients recovered – or tested negative – four days after taking Favipira, and 96 percent did so after 10 days

TBS Report
08 July, 2020, 08:10 pm
Last modified: 09 July, 2020, 11:20 am
96% of Covid-19 patients recover in Beacon pharma’s Favipira trial

Favipira double-blind trial

  • Each tablet costs Tk400
  • Beacon pharma brought it to Bangladesh in April
  • Trialled among 50 patients in 4 hospitals in Dhaka
  • 48 percent recovered or tested negative after 4 days, 96 percent after 10 days
  • For the placebo group, recovery rate was 0 percent after 4 days, 52 percent after 10 days 
  • Patients' lung conditions improved three times than placebo group members
  • No side effect in liver, kidney and carbohydrate in blood
  • Bangladesh Society of Medicine ran the trial

A clinical trial of Beacon Pharmaceuticals' Favipira tablet, to treat Covid-19 patients, has yielded a 96 percent success rate.     

Associate Professor of the medicine department of Dhaka Medical College Hospital Syed Ghulam Mogni Mowla announced the trial results at a seminar at the Westin Hotel in the capital on Wednesday.

Beacon Pharmaceutical arranged the seminar, while the Bangladesh Society of Medicine ran the trial.    

Favipiravir is the generic name of Favipira, which is known as Avigan in Japan. Beacon pharma brought it to Bangladesh in April.

Favipira was trialled among 50 patients in four hospitals in Dhaka: the Kuwait Bangladesh Friendship Government Hospital, Dhaka Mahanagar General Hospital, Kurmitola General Hospital, and Mugda Medical College and Hospital. 

Syed Ghulam said 48 percent of patients recovered or tested negative for the virus four days after taking Favipira, and 96 percent did so after 10 days.  

For the placebo group, this rate was zero percent after four days, and 52 percent after 10 days. 

Those taking Favipira showed an improvement in their lungs three times higher than those in the placebo group. 

However, patients with complex conditions or pregnant women were not given the tablet.

The medication did not result in any side effects to the patients' livers, kidneys or carbohydrates in the blood. Moreover, neither the experimental group nor the placebo group suffered any significant side effects.  

Speakers at the seminar said those who did not test positive for Covid-19 or do not have symptoms should not take Favipira. Only those who are reverse-transcription polymerase chain reaction (RT-PCR) positive should take it.

Real time RT-PCR is one of the most widely-used laboratory methods for detecting the novel coronavirus.

Each Favipira tablet costs Tk400. Patients have to complete a course of seven to 10 days based on doctors' advice and the stage of the disease. 

Professor Dr ABM Abdullah, personal physician of Prime Minister Sheikh Hasina and former dean of Bangabandhu Sheikh Mujib Medical University's medicine department, told the seminar the trial of the tablet among 50 patients could not be described as final at this moment.   

He said the trial should be run among several thousand other patients – including those in hospitals outside Dhaka. 

However, Favipira can be used now in early stages as no medicine has yet been invented to treat novel coronavirus patients, Abdullah said. 

"Asymptomatic patients routinely testing positive, however, should not be given this tablet," added the physician. 

Professor Dr Syed Modasser Ali, chairman of Bangladesh Medical Research Council, said patients have to take Favipira as per doctors' advice as there is no specific drug at this moment to treat them. 

However, they should not take it indiscriminately, he warned.

"This is not a preventive medicine. As long as there is no vaccine, there will be no preventive medication," said Modasser.

He said it would take another two years for the vaccine to be available and people should follow health guidelines until then.   

Favipira was clinically trialled in Bangladesh to know if it was effective and safe. The double-blind trial, named Dhaka Trial, was carried out as per rules of the drug directorate and Bangladesh Medical Research Council.  

Top News

Covid-19 patients / recover / Beacon Pharma / Favipira

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Export earnings hit record high $52.08B in FY22
    Export earnings hit record high $52.08B in FY22
  • Remittance inflow down by 15% in FY22 
    Remittance inflow down by 15% in FY22 
  • Photo of Bangladesh Secretariat/Collected
    Govt stops purchasing new cars for ministries, departments

MOST VIEWED

  • Photo: Collected
    2 die, 1,902 test positive for Covid-19 in 24 hours
  • Photo: Collected
    6 Covid deaths, 1,105 cases reported in 24 hours
  • Photo: Collected
    Daily Covid deaths rise to 5
  • Daily Covid deaths rise to 4 with 2,183 new cases
    Daily Covid deaths rise to 4 with 2,183 new cases
  • Illustration: Collected
    2,241 cases reported in 24 hours
  • It is paramount, again, to follow all Covid-19 health guidelines, including wearing a mask. Photo: Saikat Bhadra/TBS
    No mask, no service policy adopted again

Related News

  • Recover secures $100m minority equity investment from Goldman Sachs
  • Spanish recycled cotton producer opens new facility in Bangladesh
  • Beacon Pharma: Price Sensitive Information
  • Beacon Pharma’s profit up on sales growth
  • Dutch Covid-19 patients transferred to Germany as hospitals struggle

Features

A Glittery Eid

A Glittery Eid

5h | Mode
Rise’s target customers are people who crave to express themselves through what they wear, and their clothing line is not relegated to any age range.

Level up your Eid game with Rise

6h | Mode
Stefan Dercon, a Professor of Economics at the University of Oxford and former Chief Economist of the Department of International Development (DFID). Illustration: TBS

Renewing the ‘elite bargain’ for Bangladesh’s future growth

8h | Panorama
The eye-catching commuter: Suzuki Gixxer SF 155

The eye-catching commuter: Suzuki Gixxer SF 155

1d | Wheels

More Videos from TBS

Chirkutt performs on Fete de La Music Fest

Chirkutt performs on Fete de La Music Fest

7h | Videos
Madhuri Sanchita's seed ornaments exhibition

Madhuri Sanchita's seed ornaments exhibition

7h | Videos
Bangabandhu Tunnel to change lives of million

Bangabandhu Tunnel to change lives of million

19h | Videos
Sowari Ghat's fresh fish market

Sowari Ghat's fresh fish market

19h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
TBS Illustration
Education

Universities may launch online classes again after Eid

4
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

5
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

6
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Launch operators on various river routes see a steep drop in passengers after the opening of the the Padma Bridge. Photo: TBS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net